- About the VMC
- Pet Owners
- Farm Animal Owners
- Horse Owners
- Clinical Trials Office
Winston is an 8-year-old mixed breed dog who presented to the OSU-VMC Medical Oncology Service for evaluation of a mast cell tumor that was present on the left side of his chest. The tumor had been removed twice and had grown back both times, and now was quite large. Winston was entered into the STA-1474 clinical trial evaluating a new heat shock protein 90 (HSP90) inhibitor in dogs with mast cell tumors. He did very well throughout the 5 week study, and his tumor was almost completely gone by the end of his treatment. Winston has just finished a course of radiation therapy to hopefully get rid of any remaining tumor cells and is now enjoying his time hanging out on the front porch. Thanks to Winston and his family for helping us with this study!
Misty is a 3 year old Himalayan that presented to the OSU VMC Cardiology Service for Congestive Heart Failure (CHF) and hypertrophic obstructive cardiomyopathy (HOCM). The owner was given all the possible treatment options for Misty, and decided to enroll her into a cardiology clinical trial on 10/13/11. Misty did well throughout the 180 day trial, and continued to show no signs of CHF on physical exam, echocardiogram and thoracic radiographs. Misty completed the study last month, and at the appointment, the owner reported that Misty was doing great at home and was more active than when she started the study! She still showed no signs of CHF and the severity of her HOCM had improved since the beginning of the study. Due to these findings, we are cautiously optimistic about Misty’s long-term prognosis of living with HOCM.
Hanz is a 9.5 yr german shepherd dog that was diagnosed with OSA of the left distal radius. He underwent limb amputation on 9/29/11 and enrolled into the Palladia/Piroxicam/Cyclophosamide Treatment for Dogs with OSA clinical trial on 10/10/11. He received 4 doses of Carboplatin every 3 weeks, and on 1/13/12 was found to be free of metatisis. He was then randomized to be in the Palladia group meaning he would receive Palladia along with his Piroxicam/Cyclophosamide. He has been on this treatment for a month and doing very well.
Hanz was a active dog and always enjoyed daily walks with his owners before his diagnosis and amputation. Like most owners, they were worried about how Hanz would handle only having 3 legs and how chemotherapy would affect his quality of life. As you can see from the picture, he has maintained a great quality of life during chemotherapy and
has no issues adapting to life with 3-legs.
Charlie is an 8 year old Standard Poodle who initially came to the OSU VMC for evaluation of enlarged lymph nodes in Septmeber of this year. He was diagnosed with B cell lymphoma and he also had a very low platelet count, secondary to destruction of his platelets. He was started on standard chemotherapy and unfortunately he did not respond well. Charlie's owner then elected to enter him into a clinical trial exploring the safety and activity of a new anti-cancer drug that may be useful for the treatment of lymphoma. Charlie received KPT-276, an inhibitor of a cell protein called CRM1, every Monday, Wednesday, and Friday for 3 weeks at which point his lymphoma went into remission. Also, his platelet count became normal again on treatment. Charlie continues to receive the KPT compound now and is doing quite well. His owner reports that his energy is back and he is doing all of the things he loves to do including competing in agility trials.